Skip to content

Author

Wen-Long Wan

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer.

Given the persistently poor five-year survival rate (<10 %) in metastatic bladder cancer (BLCA) and the limited efficacy of conventional chemotherapy and programmed cell death protein 1 (PD-1) inhibitor monotherapy, there is an urgent need to identify novel immune targets and rational combination strategies. Therefore,...

Wen-Long Wan, Fang Wei, Lu Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.